Navigating Recent Advances in the Treatment of Advanced Renal Cell Carcinoma (RCC): Expert Strategies on Immunotherapy Combination Regimens

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2020 to August 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
Bristol-Myers Squibb, Exelixis, and Merck Sharp & Dohme Corp.

Description:
Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases. In 2020, it is estimated that there will be approximately 73,820 new cases of kidney cancer. Approximately 16% of patients with RCC will have metastases at diagnosis, and as many as 40% will demonstrate metastasis after primary surgical treatment for localized RCC. With a 5-year survival rate ranging from 5% to 12%, the prognosis for any treated renal cell cancer patient with progressing, recurring, or relapsing disease is poor, regardless of cell type or stage. Almost all patients with advanced renal cell cancer are incurable. Fortunately for patients with advanced RCC, many new treatments have recently become available or have completed clinical trials. The question and selection of treatment depends on many factors, including if there has been any previous treatment and site of recurrence, as well as individual patient considerations. Fortunately, clinicians are being equipped with immune checkpoint inhibitors, both alone and in combination, to integrate into the advanced RCC treatment paradigm, which individualize therapy for patients with advanced RCC, ultimately improving patient outcomes and quality of life. These new options, some of which have been approved and others that are currently undergoing clinical trials or regulatory review, have shown improved efficacy and safety in advanced RCC.

Upon completion of this activity, participants will be able to:

  • Identify current unmet clinical needs in the management of advanced renal cell carcinoma (RCC) and evidence-based recommendations for the care of patients with these tumors

  • Review the efficacy and safety of approved and emerging immunotherapies, including newer combination options, in the management of advanced RCC

  • Assess the rationale for the development and use of immune checkpoint inhibitor combination therapies in the management of advanced RCC

  • Analyze strategies to optimally sequence immunotherapy in advanced RCC management

  • Explore strategies to monitor and manage adverse events associated with immunotherapies and immunotherapy combination options in advanced RCC in order to improve patient adherence and quality of life

  • Discuss the managed care considerations of current and emerging immunotherapies and combinations by exploring where these agents fit into the current advanced RCC management paradigm

     

Faculty: Sumanta Kumar Pal, MD
Associate Clinical Professor
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope Comprehensive Cancer Center

Disclosure:

Dr. Pal serves as a consultant to Astellas, Aveo, BMS, Eisai, Exelixis, Ipsen, Genentech, Novartis, Pfizer, and Roche. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
Bristol-Myers Squibb, Exelixis, and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue